SCHEMBL1679477

SCHEMBL1679477

CN(C)CCNC(=O)c1cccc(-c2cnc(N)c(-c3ccnc(Cl)c3)c2)c1

nearest known ligand 0.68

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PRKD3 O94806 1/20 0.68
PRKD1 Q15139 1/20 0.68
PRKD2 Q9BZL6 1/20 0.68
FYN P06241 9/20 0.62
MAP4K4 O95819 2/20 0.51
CHEK2 O96017 1/20 0.48
CAMK2D Q13557 3/20 0.46
RAD52 P43351 1/20 0.44
IGF1R P08069 1/20 0.44
CHUK O15111 1/20 0.44
INSR P06213 1/20 0.44
MAPK8 P45983 1/20 0.44
CAMKK2 Q96RR4 1/20 0.44
PDE1A P54750 1/20 0.44
PDE1B Q01064 1/20 0.44
PDE4D Q08499 1/20 0.44
PDE7A Q13946 1/20 0.44
PDE1C Q14123 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1679122 0.90 PRKD3 (0.69) PRKD3PRKD1PRKD2FYNMAP4K4
SCHEMBL1679184 0.90 PRKD3 (0.71) PRKD3PRKD1PRKD2FYNMAP4K4
SCHEMBL1679539 0.90 PRKD3 (0.71) PRKD3PRKD1PRKD2FYNMAP4K4
SCHEMBL1679192 0.89 PRKD3 (0.70) PRKD3PRKD1PRKD2FYNMAP4K4
SCHEMBL1679744 0.88 PRKD3 (0.69) PRKD3PRKD1PRKD2FYNMAP4K4
SCHEMBL14189985 0.88 PRKD3 (0.74) PRKD3PRKD1PRKD2FYNMAP4K4
SCHEMBL1679743 0.88 PRKD3 (0.74) PRKD3PRKD1PRKD2FYNMAP4K4
SCHEMBL1679144 0.87 PRKD3 (0.69) PRKD3PRKD1PRKD2FYNMAP4K4
SCHEMBL1679177 0.87 PRKD3 (0.73) PRKD3PRKD1PRKD2FYNMAP4K4
SCHEMBL1679430 0.85 PRKD3 (0.74) PRKD3PRKD1PRKD2FYNMAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098325-A1 PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2011-04-28 US claimed
US-20110098325-A1 PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2011-04-28 US disclosed
US-20110098325-A1 PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2011-04-28 US disclosed
US-20110098325-A1 PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2011-04-28 US disclosed
WO-2008074997-A1 PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098325-A1 PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS PKD2, PKD1, BAZ2B PRKD3 38/4885PRKD1 33/4885PRKD2 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.